Eflornithine hydrochloride hydrate (DFMO hydrochloride hydrate) is a specific and irreversible inhibitor of the ornithine decarboxylase (ODC). Eflornithine hydrochloride hydrate has antitumor activity and has also been used in the hirsutism Eflornithine hydrochloride hydrate has antitumor activity and is also used in the treatment of hirsutism.

When cultured cells are treated with α-difluoromethyl-Orn, an inhibitor of polyamine biosynthesis, production of hydrogen peroxide is suppressed and programmed cell death did not occur[1].

Eflornithine stands as the only novel compound registered for human African trypanosomiasis treatment in the past five decades, primarily serving as an alternative for cases resistant to melarsoprol involving Trypanosoma brucei gambiense. Additionally, a 15% eflornithine cream demonstrates efficacy superior to placebo in diminishing excessive, unwanted facial hair growth in patients, with 58% of individuals treated with eflornithine observing at least some improvement in facial hirsutism after 24 weeks, compared to 34% of those receiving placebo. Furthermore, the inhibitory effect on hair growth by eflornithine cream is significantly amplified when applied to mouse skin previously treated with microneedles. In hypertensive rats with coarctation, eflornithine treatment normalizes contractile responses to KCI and norepinephrine, and enhances relaxations to acetylcholine within 14 days, indicating its broader pharmacological utility.

BY2 cells are treated with or without cryptogein in the presence or absence of DFMO(Difluoromethylornithine) and monitered the effect of chemicals on cell growth. (Only for Reference)

DMSO: 2.77 mg/mL (11.71 mM), Sonication is recommended.

H2O: 123.75 mg/mL (522.95 mM), Sonication is recommended.